Timothy Eugene Sullivan Sells 546 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 546 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $16,117.92. Following the transaction, the chief financial officer now directly owns 128,665 shares in the company, valued at $3,798,190.80. This represents a 0.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total value of $93,967.84.
• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ:APLS traded up $0.99 during mid-day trading on Thursday, hitting $30.46. 232,907 shares of the company traded hands, compared to its average volume of 1,954,741. The firm has a market cap of $3.79 billion, a P/E ratio of -14.99 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90. The firm’s 50 day simple moving average is $32.20 and its 200 day simple moving average is $32.96.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same quarter last year, the business earned ($1.17) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% compared to the same quarter last year. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Needham & Company LLC lowered their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective on the stock. Mizuho decreased their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. William Blair initiated coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company reduced their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently bought and sold shares of APLS. Squarepoint Ops LLC acquired a new stake in Apellis Pharmaceuticals during the 2nd quarter valued at approximately $2,350,000. AQR Capital Management LLC grew its position in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after acquiring an additional 190,420 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Apellis Pharmaceuticals in the 2nd quarter worth approximately $725,000. Duncan Williams Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $609,000. Finally, Handelsbanken Fonder AB grew its position in shares of Apellis Pharmaceuticals by 15.5% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,600 shares of the company’s stock worth $796,000 after acquiring an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).